For the Inventor, By the Inventor

Enter assignee name

Montreal, Canada

Methylgene, Inc.

USPTO Granted Patents = 53

CIPO Patents = 8

EPO Patents = 15

Forward Citations = 537

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Arkadii Vaisburg (28 out of 33 patents)

Stephen Claridge (14 out of 20 patents)

Lijie Zhan (14 out of 14 patents)

4. Daniel Delorme (13 out of 38 patents)

5. Ljubomir Isakovic (12 out of 12 patents)

6. Michael Mannion (12 out of 12 patents)

7. Stephane Raeppel (12 out of 14 patents)

8. Jeffrey M Besterman (11 out of 12 patents)

9. Silvana Leit (10 out of 11 patents)

10. Oscar Mario Saavedra (10 out of 10 patents)

11. Sylvie Frechette (10 out of 10 patents)

12. Franck Raeppel (9 out of 13 patents)

13. Jubrail Rahil (9 out of 10 patents)

14. Oscar Miguel Moradei (8 out of 32 patents)

15. Frederic Gaudette (8 out of 8 patents)

Core Competencies:

Histone Deacetylase Inhibitors

Protein Tyrosine Kinase Inhibitors

Fused Heterocyclic Kinase Inhibitors

VEGF Receptor Inhibitors

HGF Receptor Signaling

Beta-Lactamase Inhibitors

Gene Expression Modulation

Antisense Oligonucleotides

DNA Methyltransferase Inhibitors

Dibenzo[b,f][1,4]oxazepin

Small Molecule Inhibitors

Combination Therapy

53 patents: Sort by Forward Citations

1. 9193749 - Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors (2015-11-24),

2. 9096565 - Inhibitors of histone deacetylase (2015-08-04),

3. 9018378 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2015-04-28),

4. 8907091 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2014-12-09),

5. 8906852 - Inhibitors of protein tyrosine kinase activity (2014-12-09),

6. 8846927 - Inhibitors of protein tyrosine kinase activity (2014-09-30),

7. 8796330 - Inhibitors of histone deacetylase and prodrugs thereof (2014-08-05),

8. 8759522 - Inhibitors of protein tyrosine kinase activity (2014-06-24),

9. 8759400 - Histone deacetylase inhibitors for enhancing activity of antifungal agents (2014-06-24),

10. 8729268 - Inhibitors of protein tyrosine kinase activity (2014-05-20),

11. 8673911 - Inhibitors of histone deacetylase (2014-03-18),

12. 8598168 - Inhibitors of histone deacetylase (2013-12-03),

13. 8569503 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2013-10-29),

14. 8470850 - Inhibitors of VEGF receptor and HGF receptor signalling (2013-06-25),

15. 8455484 - Selected inhibitors of protein tyrosine kinase activity (2013-06-04),

MethylGene, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of cancer. Their innovative approach uses epigenetic modulation to target and inhibit abnormal gene expression involved in cancer proliferation. With a strong pipeline of potential therapeutics, MethylGene aims to make a significant impact in improving cancer patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

53 Patents

#18 in Montreal

#244 in Canada

#12,943 in the World

Montreal, Canada

Methylgene, Inc.

Forward Citations = 537

79 inventors:

Arkadii Vaisburg (28 out of 33 patents)

Stephen Claridge (14 out of 20 patents)

Lijie Zhan (14 out of 14 patents)

4. Daniel Delorme (13 out of 38 patents)

5. Ljubomir Isakovic (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…